Scientific News:Recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.October, 2022

at
Categories
Tags

Related posts

April 25, 2021

Gut-dwelling bacterium singled out as the possible cause of colorectal cancer Some strains of the ‘Morganella morganii’ microbe produce molecules that are toxic for human DNA

Read more
July 12, 2018

FDA Grants Accelerated Approval to Teclistamab-cqyv in Relapsed/Refractory Multiple Myeloma

Read more
April 25, 2021

Avelumab Plus Axitinib Shows Promising Activity in Pretreated Advanced Type B3 Thymoma and Thymic Carcinoma October, 2022

Read more